Paper Details

  1. Home
  2. Paper Details

Dose-dependent efficacy of miglitol, an alpha-glucosidase inhibitor, in type 2 diabetic patients on diet alone: results of a 24-week double-blind placebo-controlled study.

Author: DrentM L, HoenderdosE B M, JonkerJ J C, TollefsenA T M, van HeusdenF H J A, van der VeenE A

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Miglitol, an alpha-glucosidase inhibitor, effectively lowers HbA1c levels and postprandial glucose and insulin levels in Type 2 diabetic patients on diet alone in a dose-dependent manner. The optimal dose appears to be 50 to 100 mg t.i.d., as higher doses are associated with increased gastrointestinal side effects, leading to a higher dropout rate.
Paper Details　
Original Abstract of the Article :
AIMS: A double-blind randomised study was performed to compare the dose-effect and dose-tolerability relationships between the alpha-glucosidase inhibitor miglitol in doses of 25 mg, 50 mg, 100 mg and 200 mg all t.i.d. vs placebo t.i.d. in patients with Type 2 diabetes mellitus on diet only. METHOD...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/12173729

データ提供：米国国立医学図書館（NLM）

Miglitol: A Dose-Dependent Oasis in the Desert of Type 2 Diabetes

Imagine a desert of high blood sugar, where type 2 diabetes can wreak havoc on the body. This double-blind, placebo-controlled study explores the efficacy of miglitol, an alpha-glucosidase inhibitor, in patients with type 2 diabetes. The researchers investigated the dose-dependent effects of miglitol, akin to exploring different paths through a desert to find the most effective route to a hidden oasis.

Mapping the Desert of Glycemic Control: Finding the Optimal Dose of Miglitol

The study found that miglitol was effective in lowering blood sugar levels in a dose-dependent manner. Higher doses of miglitol led to greater reductions in HbA1c levels and postprandial glucose and insulin levels. However, the study also found that the incidence of gastrointestinal side effects, such as flatulence, diarrhea, and abdominal pain, increased with higher doses. These findings highlight the importance of finding the optimal dose of miglitol, balancing efficacy with tolerability.

Finding a Balance: Maximizing Benefits and Minimizing Side Effects

This study underscores the importance of individualizing treatment for type 2 diabetes. While miglitol offers a potential oasis for glycemic control, it's crucial to find the right dose to maximize benefits and minimize side effects. Healthcare professionals should work closely with patients to determine the optimal dose of miglitol based on individual needs and responses.

Dr. Camel's Conclusion

This study, like a camel caravan searching for the optimal route through a desert of high blood sugar, reveals the dose-dependent efficacy of miglitol. The findings suggest that this medication can be a valuable tool for managing type 2 diabetes, but careful dose optimization is essential to balance benefits and minimize side effects. It's important to consult with a healthcare professional to determine the best approach for managing type 2 diabetes.

Date :
  1. Date Completed 2003-01-29
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

12173729

DOI: Digital Object Identifier

12173729

Related Literature

Article Analysis
・Side Effects of miglitol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.